Cholesterol Lowering and Residual Risk in Diabetes, Type 1
Phase 4
125
about 4.7 years
18–89
4 sites in NY
About this study
Researchers are testing whether lowering cholesterol can improve platelet function, white blood cell gene expression, and vascular function in people with type 1 diabetes. The trial will follow participants for about two years to observe these effects.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take 18F-FDG
- 2.Take Atorvastatin Calcium Tablets
- 3.Take Evolocumab Cartridge
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
fludeoxyglucose (18F), atorvastatin (Statin; inhibits HMG-CoA reductase to lower cholesterol), CARDIOVASCULAR SYSTEM, ezetimibe (Cholesterol absorption inhibitor; reduces intestinal cholesterol uptake)
oral, subcutaneous
Endocrinology